Eli Lilly & Company and ScinoPharm Taiwan Ltd. Announce Settlement of Gemcitabine Litigation

July 30, 2009

TAINAN, Taiwan, July 30 /PRNewswire-Asia/ — Eli Lilly & Company (“Lilly”)
and ScinoPharm Taiwan Ltd. (“ScinoPharm”) announced today that they have
reached an amicable resolution of all ongoing patent litigations between the
companies relating to ScinoPharm’s manufacture and sale of gemcitabine
hydrochloride around the world.

As part of the settlement, Lilly has granted ScinoPharm a royalty bearing
license to manufacture and sell gemcitabine hydrochloride (API) throughout the
world, excluding only countries where the Lilly compound or method of use
patents remain in force and the United States.

About ScinoPharm Taiwan Ltd.

ScinoPharm Taiwan Ltd. is a leading process R&D and API manufacturing
service provider to the global pharmaceutical industry. With cGMP production
facilities, ScinoPharm offers a wide portfolio of services ranging from custom
synthesis for early phase pharmaceutical activities to brand companies as well
as APIs for the generic industry. Combining cost-effective resources and
productivity of Asia along with extensive regulatory know-how, ScinoPharm is
uniquely positioned to serve global pharmaceutical R&D and manufacturing needs
at any level and for any company in this sector. For more information please
visit http://www.scinopharm.com .

About Eli Lilly & Company

Lilly, a leading innovation-driven corporation, is developing a growing
portfolio of pharmaceutical products by applying the latest research from its
own worldwide laboratories and from collaborations with eminent scientific
organizations. Headquartered in Indianapolis, Indiana, Lilly provides answers
– through medicines and information — for some of the world’s most urgent
medical needs. Additional information about Lilly is available at
http://www.lilly.com .

    Media Contact:

    ScinoPharm Taiwan, Ltd.
    Jessie Wang
    Tel:   +886-6-505-2888
    Email: Jessie.wang@scinopharm.com.tw

SOURCE ScinoPharm Taiwan, Ltd.

Source: newswire

comments powered by Disqus